No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Qingdao Vland Biotech Inc. specializes in the research, development, and production of enzymes, probiotics, animal vaccines, and veterinary health products. Its extensive product range features enzymes for animal feed, industrial uses, and food processing, along with various probiotics, such as aquaculture premixes, general health supplements, and both animal and plant-specific formulations. The company also provides a comprehensive array of animal vaccines and biological solutions, including both live and inactivated vaccines for poultry and swine, in addition to antibodies. Its offerings extend to poultry pharmaceuticals, covering antiparasitic, antiviral, and nutritional medications, alongside disinfectants. Furthermore, it supplies traditional Chinese veterinary remedies designed for aquatic species, poultry, and livestock, including laying hens. Vland Biotech's diverse clientele operates across numerous sectors, such as agriculture, animal husbandry, textile manufacturing, papermaking, household cleaning and detergents, food production, biofuel development, and environmental protection. This entity, established in 2005 and headquartered in Qingdao, China, operates as a subsidiary of Qingdao Kangdien Industrial Co., Ltd.
www.vlandgroup.comNo one on the platform currently holds 603739.SS.
No tracked institution reports a position in 603739.SS as of their last filing.
No one on the platform has traded 603739.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.3% | 5.4% | 10.7% | — | — | — |
| Rev. Growth % | 3.4% | 7.3% | ||||
| Profit Margin % | 5.1% | 6.8% | 8.6% | |||
| Free Cash Flow Margin % | 2.5% | -10.4% | -3.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.5B | +4.1% | $0.32 | $0.29–$0.35 | — | 2 |
| 2027 | $1.7B | +10.6% | $0.34 | $0.31–$0.37 | — | 2 |
| 2028 | $1.9B | +11.0% | $0.37 | $0.36–$0.38 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 603739.SSQingdao Vland Biotech Inc. | $12.13 | -0.90% | $3.1B | — |
| 002286.SZBaolingbao Biology Co.,Ltd. | $7.69 | +0.26% | $2.9B | — |
| 300238.SZGuanhao Biotech Co.,Ltd. | $10.88 | +0.83% | $2.9B | — |
| 300653.SZYantai Zhenghai Biotechnology Co., Ltd. | $14.58 | +0.55% | $2.6B | — |
| 300878.SZZhejiang Wecome Pharmaceutical Company Limited | $31.89 | +1.24% | $4.5B | — |
| 603718.SSShanghai Hile Bio-Technology Co., Ltd. | $3.01 | +0.67% | $2.0B | — |
| 603896.SSZhejiang Shouxiangu Pharmaceutical Co., Ltd. | $14.03 | -0.36% | $2.8B | — |
Source: Financial Modeling Prep · peers by sector/industry